This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Abstract: Trans-resveratrol is a naturally occurring polyphenolic compound found in a variety of foods, but predominantly in grapes. Safety studies were conducted on high-purity trans-resveratrol (Resvida), including skin and eye irritation, dermal sensitisation, subchronic and reproductive toxicity, genotoxicity, absorption, metabolism and excretion. ResVida was nonirritating to skin and eyes, and nonsensitising. It was nonmutagenic in a bacterial reverse mutation assay in Salmonella typhimurium and Escherichia coli, but exhibited clastogenic activity in a chromosomal aberration test in human lymphocytes. However, in an in vivo bone marrow micronucleus test in rats, resVida was nongenotoxic. In a 28-day study, resVida caused no adverse effects in rats at 50, 150 and 500mg/kg body weight/day. Similarly, in a 90-day study, resVida did not cause any adverse effects in rats at up to 700mg/kg body weight/day — the highest dose tested. ResVida did not induce any adverse reproductive effects in an embryo-fetal toxicity study in rats at a dose of 750mg/kg body weight/day. Also, in vitro and in vivo absorption, metabolism and excretion studies in Caco-2 cells, rat primary hepatocytes and male and female rats (in vivo) show that Resvida is readily absorbed, metabolized and excreted. These studies provide evidence that Resvida is well tolerated and nontoxic.

Potential applications: Resveratrol has been demonstrated in various animal models to extend lifespan; improve cardiovascular health; improve balance, co-ordination and endurance; improve insulin sensitivity and glucose utilisation. ResVida is self-affirmed GRAS, is 99 per cent pure and is free from pesticide and herbicide residues.

Specifically, after two weeks, 32 per cent of the subjects in the placebo group reported URTI symptoms, compared with only 10 per cent in the group taking 250mg Wellmune WGP. At four weeks, 28 per cent of the placebo group reported URTI symptoms, compared with eight per cent in the group taking Wellmune WGP. In addition, the Wellmune WGP group reported a 41 per cent increase in general health when compared with the placebo group over the four-week study period. In comparison with the placebo group, the Wellmune WGP group reported statistically significant increases in vigour, and reductions in fatigue (38 per cent), tension (19 per cent), and confusion (15 per cent).

The psychological health assessment was obtained with a POMS questionnaire, which measures vigour, fatigue, tension, confusion, depression and anger. The POMS profile has been used in more than 2,900 health studies.

Potential applications: For stress and immune health, Wellmune WGP is designed for foods, beverages and supplements.